In this study, we sought to assess the utility of NfL as a biomarker of disease progression and cerebellar pathology in a preclinical mouse model of SCA3 by characterizing changes in blood NfL levels throughout disease progression in YACQ84 mice. The gene discussed is NEFL; the disease is Spinocerebellar ataxia type 3.